Literature DB >> 8763846

Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1.

R M Batchelder1, W R Wilson, M P Hay, W A Denny.   

Abstract

The enediyne anti-tumour antibiotics are extremely potent cytotoxins, apparently because of their conversion to diradical species which induce DNA double strand breaks with high efficiency. The potency of enediynes suggests their possible utility as effector units for prodrugs which can be activated selectively in tumours, such as bioreductive drugs (BD) or radiation-activated cytotoxins (RAC). However, the similarity of the radical-induced DNA breakage reactions of the enediynes to those caused by ionising radiation suggested that resistance of hypoxic cells might be a potential problem. Experiments with AA8 cells in culture demonstrated that the enediyne antibiotics neocarzinostatin and esperamicin A, (ESP) are much less toxic under hypoxic than aerobic conditions. Sensitivity to ESP (concentration for 90% cell kill 10 pM) decreased 15-fold under hypoxia, and was partially restored by simultaneous exposure to misonidazole. ESP induced chromosome breakage (micronucleus formation) with an efficiency similar to gamma radiation at equivalent cell kill, suggesting a clastogenic mechanism of cytotoxicity. In contrast, little micronucleus formation was evident after exposure to ESP under hypoxia, even at concentrations giving equivalent cell killing. These findings suggest that resistance of hypoxic cells may limit the utility of enediynes as cytotoxic effectors for BD or RAC prodrug development, and that further investigation of enediynes as anti-tumour agents should include strategies capable of eliminating hypoxic cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763846      PMCID: PMC2150004     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  11 in total

Review 1.  Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin.

Authors:  P C Dedon; I H Goldberg
Journal:  Chem Res Toxicol       Date:  1992 May-Jun       Impact factor: 3.739

2.  Designed enediynes: a new class of DNA-cleaving molecules with potent and selective anticancer activity.

Authors:  K C Nicolaou; W M Dai; S C Tsay; V A Estevez; W Wrasidlo
Journal:  Science       Date:  1992-05-22       Impact factor: 47.728

Review 3.  Free radical mechanisms in neocarzinostatin-induced DNA damage.

Authors:  I H Goldberg
Journal:  Free Radic Biol Med       Date:  1987       Impact factor: 7.376

4.  Measurement of micronuclei in lymphocytes.

Authors:  M Fenech; A A Morley
Journal:  Mutat Res       Date:  1985 Feb-Apr       Impact factor: 2.433

5.  A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells.

Authors:  G J Finlay; B C Baguley; W R Wilson
Journal:  Anal Biochem       Date:  1984-06       Impact factor: 3.365

6.  Radiosensitization of mammalian cells in vitro by nitroacridines.

Authors:  P B Roberts; W A Denny; L P Wakelin; R F Anderson; W R Wilson
Journal:  Radiat Res       Date:  1990-08       Impact factor: 2.841

7.  Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

Authors:  L M Hinman; P R Hamann; R Wallace; A T Menendez; F E Durr; J Upeslacis
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

8.  Nitroaromatic radiation sensitizers substitute for oxygen in neocarzinostatin-induced DNA damage.

Authors:  L S Kappen; I H Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

9.  Cell-specific regulation of apoptosis by designed enediynes.

Authors:  K C Nicolaou; P Stabila; B Esmaeli-Azad; W Wrasidlo; A Hiatt
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

10.  Competition between anaerobic covalent linkage of neocarzinostatin chromophore to deoxyribose in DNA and oxygen-dependent strand breakage and base release.

Authors:  L F Povirk; I H Goldberg
Journal:  Biochemistry       Date:  1984-12-18       Impact factor: 3.162

View more
  8 in total

Review 1.  Recent developments in the design of bioreductive drugs.

Authors:  W A Denny; W R Wilson; M P Hay
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  Explorations of catalytic domains in non-ribosomal peptide synthetase enzymology.

Authors:  Gene H Hur; Christopher R Vickery; Michael D Burkart
Journal:  Nat Prod Rep       Date:  2012-07-17       Impact factor: 13.423

3.  TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Authors:  Qian Liu; Jessica D Sun; Jingli Wang; Dharmendra Ahluwalia; Amanda F Baker; Lee D Cranmer; Damien Ferraro; Yan Wang; Jian-Xin Duan; W Steve Ammons; John G Curd; Mark D Matteucci; Charles P Hart
Journal:  Cancer Chemother Pharmacol       Date:  2012-03-02       Impact factor: 3.333

4.  The radiomimetic enediyne, 20'-deschloro-C-1027 induces inter-strand DNA crosslinks in hypoxic cells and overcomes cytotoxic radioresistance.

Authors:  Terry A Beerman; Loretta S Gawron; Ben Shen; Daniel R Kennedy
Journal:  DNA Repair (Amst)       Date:  2014-06-28

5.  Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Authors:  Sant P Chawla; Lee D Cranmer; Brian A Van Tine; Damon R Reed; Scott H Okuno; James E Butrynski; Douglas R Adkins; Andrew E Hendifar; Stew Kroll; Kristen N Ganjoo
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

6.  C-1027, a radiomimetic enediyne anticancer drug, preferentially targets hypoxic cells.

Authors:  Terry A Beerman; Loretta S Gawron; Seulkih Shin; Ben Shen; Mary M McHugh
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 7.  Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells.

Authors:  Marica Garziera; Lucia Scarabel; Giuseppe Toffoli
Journal:  J Immunol Res       Date:  2017-07-11       Impact factor: 4.818

8.  Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy.

Authors:  Chan Joo Yeom; Lihua Zeng; Yuxi Zhu; Masahiro Hiraoka; Hiroshi Harada
Journal:  Cancers (Basel)       Date:  2011-09-15       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.